Ayasdi Launches Ayasdi Cure Application to Catalyze Next Generation Precision Medicine
Ayasdi Announces 400% Performance Improvement for Real-Time Analysis of Life Science Data with Intel Xeon Processor-Based Platforms
CLC bio, QIAGEN Company, and Ayasdi Partner to Help Scientists Make Discoveries in Genetic Sequencing Data
April 29, 2014
Menlo Park, CA and Boston, MA at Bio-IT -- April 29, 2014 -- Today at Bio-IT World Conference and Expo 2014, Ayasdi (www.ayasdi.com) launched Ayasdi Cure, a new application designed to help pharmaceutical and biotech companies accelerate the drug discovery process by 50% in the era of precision medicine. Ayasdi Cure runs on Ayasdi's award-winning machine learning platform, which merges hundreds of algorithms with Topological Data Analysis (TDA) and obviates the need for queries or coding.
- By optimizing Ayasdi Cure for Intel® Xeon® processor features including the Intel® Math Kernel Library (MKL) and Intel® Advanced Vector Extensions (AVX), Ayasdi was able to improve performance by 400% percent. These results are part of ongoing work between the two companies to optimize Ayasdi platforms for Intel-based technologies to dramatically improve the time from data to insight.
- CLC bio will providing all 2,500 CLC bio customer organizations with access to Ayasdi Cure, through a seamless integration with CLC bio's bioinformatics platform, to help them discover new insights in genetic sequencing data.
To learn more about Ayasdi Cure and the partnerships announced today, join Dr. Pek Lum, Chief Data Scientist and VP of Solutions at Ayasdi and a customer on stage at Bio-IT or visit Ayasdi's booth (#145).
Dramatically Cutting the Time, Cost, and Effort of Drug Development
According to a recent report by PhRMa, on average it takes 10-15 years to develop a drug and costs more than $1.2B, with many industry estimates putting that cost even higher. This reality makes each potential drug an enormous investment, forcing pharmaceutical companies to find and implement operational efficiencies throughout the entire process. Current advanced analytics solutions rely on large teams of Data Scientists to formulate hypotheses and write code and that can take weeks, and often months at every stage of development, lengthening the entire process considerably. Even then, the probability of discovering critical insights is low because there are too many questions to ask and not enough Data Scientists to ask them.
By contrast, the Ayasdi Cure application streamlines the discovery process—including Research and Discovery, Compound Selection, Preclinical Testing, Clinical Testing, and Regulatory Review—by rapidly identifying compounds, drug targets, biomarkers, and adverse events from a variety of public and private biological and clinical data. Ayasdi Cure reduces the time and cost associated with this process by lowering analysis time and discovering novel insights.
By revealing patterns and subgroups in a visualization-based user interface, Ayasdi Cure makes it easy for biologists, chemists, and physicians to consume and derive value from complex data.
In addition to accelerating the drug development process, Life Sciences companies can also use the Ayasdi Cure application to support the following activities, all fueling faster, more accurate Precision Medicine:
- Biomarker Discovery
- Patient Segmentation, and
- Adverse Effects Discovery.
Key features of the Ayasdi Cure application include:
- Compound visualization
- Next Generation Sequencing (NGS) Genomic Viewer
- Molecular pathways (GO processes, KEGG, PPI, Mesh Terms, miRNA, and more.)
"One of Intel's core strengths is expertise in optimizing hardware and software for highly complex data computation. We're able to maximize the benefits gained from using the Intel architecture," said Ketan Paranjape, Director of Personalized Medicine at Intel. "By optimizing and tuning Ayasdi Cure application, we can reduce the time and cost of delivering insights to data scientists, biologists, clinicians, and others who work with data in life sciences."
"Ayasdi Cure doesn't try to find answers to questions that are already known, but instead finds questions that no one has thought to ask," said Mikael Flensborg, Director of Global Partner Relations at CLC bio, a QIAGEN Company. "By offering Ayasdi Cure to our customer network of 2,500 institutions and over 100,000 users globally, CLC bio is enabling pharmaceutical and biotech companies to understand their sequencing data in a more holistic way, unlocking previously undiscovered hypotheses."
"As the price of sequencing decreases over time, we believe that a higher percentage of diagnoses will be made based on genetic testing. This will dramatically increase the amount of NGS data that pharmaceutical companies have—leading to deeper insights, more efficacious drugs, and better patient outcomes," said Dr. Pek Lum, Chief Data Scientist and VP of Solutions at Ayasdi. "This dramatic increase in genetic data will create some of the largest and complex datasets in the world that will render most advanced analytics tools unworkable. By instantly displaying the shape of genetic and clinical data, Ayasdi Cure will help biotech companies develop therapies faster than ever before."
Separately, Ayasdi also announced today Ayasdi Cure and a partnership with U-BIOPRED. To read more, click here.
About CLC bio
CLC bio, a QIAGEN company based in Aarhus, Denmark, was founded in 2005 and has created the leading commercial data analysis platform for next-generation sequencing (NGS). It serves leading research institutions and top pharmaceutical companies worldwide. CLC bio's solutions are used as an integrating workbench to handle biological data generated by a sequencer through a series of analysis stages. CLC bio's leading products are CLC Genomics Workbench, a comprehensive and user-friendly analysis package for analyzing, comparing and visualizing NGS data; and CLC Genomics Server, a flexible enterprise-level infrastructure and analysis backbone for NGS data analysis. For more information, please visit http://www.clcbio.com
QIAGEN N.V. is a Netherlands holding company publicly traded on NASDAQ and Frankfurt Prime Standard. The Company is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular insights. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of September 30, 2013, QIAGEN employed more than 4,100 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com
Ayasdi is transforming how the world uses data to solve complex problems by automatically discovering and operationalizing insights from complex datasets. Founded in 2008 after a decade of DARPA and NSF funded research at Stanford, the Ayasdi Platform executes and merges the results of hundreds of machine learning algorithms using Topological Data Analysis (TDA), enabling users to explore their data within interactive and intuitive applications. Funded by Khosla Ventures, Institutional Venture Partners, GE Ventures, Citi Ventures, and FLOODGATE, Ayasdi's customers include General Electric, Citigroup, Anadarko, Boehringer Ingelheim, the University of California San Francisco (UCSF), and Mount Sinai Hospital. To learn more, visit www.ayasdi.com or follow us @ayasdi.
Ayasdi helps the world's biggest and most sophisticated organizations discover breakthroughs that change how we all live and work. People who share this passion can view Ayasdi career opportunities here.
Intel and Xeon are registered trademarks of Intel Corporation in the United States and other countries.